KALA Kala Pharmaceuticals Inc
Price (delayed)
$4.77
Market cap
$30.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.15
Enterprise value
$11.85M
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Highlights
Kala Pharmaceuticals's equity has surged by 80% QoQ and by 64% YoY
The EPS rose by 41% year-on-year and by 17% since the previous quarter
KALA's quick ratio has plunged by 50% YoY but it is up by 47% from the previous quarter
Key stats
What are the main financial stats of KALA
Market
Valuations
Earnings
Shares outstanding
6.45M
Market cap
$30.78M
Enterprise value
$11.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$40.43M
Net income
-$38.51M
EBIT
-$32.73M
EBITDA
-$32.14M
Free cash flow
-$29.59M
Per share
Balance sheet
Liquidity
EPS
-$10.15
EPS diluted
-$10.15
Free cash flow per share
-$7.79
Book value per share
$2.67
Revenue per share
$0
TBVPS
$14.62
Total assets
$55.48M
Total liabilities
$43.15M
Debt
$32.25M
Equity
$12.33M
Working capital
$35.84M
Debt to equity
2.62
Current ratio
3.11
Quick ratio
3.02
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68.7%
Return on equity
-389.3%
Return on invested capital
-142.4%
Return on capital employed
-84.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALA stock price
How has the Kala Pharmaceuticals stock price performed over time
Intraday
-16.75%
1 week
-27.4%
1 month
-31.17%
1 year
-40.3%
YTD
-31.27%
QTD
-16.75%
Financial performance
How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.43M
Net income
-$38.51M
Gross margin
N/A
Net margin
N/A
Kala Pharmaceuticals's net income has increased by 9% YoY
KALA's operating income is down by 3.9% YoY
Growth
What is Kala Pharmaceuticals's growth rate over time
Valuation
What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 41% year-on-year and by 17% since the previous quarter
Kala Pharmaceuticals's equity has surged by 80% QoQ and by 64% YoY
The price to book (P/B) is 31% lower than the 5-year quarterly average of 3.1 and 24% lower than the last 4 quarters average of 2.8
Efficiency
How efficient is Kala Pharmaceuticals business performance
The return on equity has declined by 38% year-on-year but it is up by 13% since the previous quarter
The ROIC fell by 33% YoY and by 13% QoQ
The company's return on assets fell by 4.1% YoY
Dividends
What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALA.
Financial health
How did Kala Pharmaceuticals financials performed over time
The total assets is 29% more than the total liabilities
KALA's current ratio has shrunk by 51% YoY but it is up by 45% QoQ
KALA's quick ratio has plunged by 50% YoY but it is up by 47% from the previous quarter
KALA's debt is 162% higher than its equity
Kala Pharmaceuticals's equity has surged by 80% QoQ and by 64% YoY
The debt to equity has plunged by 51% from the previous quarter and by 46% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.